Pacira BioSciences, Inc.
PCRX· Nasdaq
Released Feb 26, 2021, after the close
10-K filed Mar 1, 2021, 60 days after period end · 0001396814-21-000014
No earnings release is on file for this quarter. Its figures came with the 10-K.
| Metric | Q4 2020 | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $130.97M | $122.42M | $95.12M | $79.08M |
| Net Income | $14.51M | -$4.89M | $8.29M | $4.60M |
| EPS Diluted | $0.32 |
Pacira BioSciences, Inc. · CIK 1396814 · Engraved from SEC EDGAR
| -$0.12 |
| $0.20 |
| $0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.